Portfolio

AMLo Biosciences

Healthcare & Biotechnology

Get in touch

Company Bio

AMLo Biosciences is developing a diagnostic kit to accurately predict melanomas that are genuinely low-risk and those that are high-risk with greater sensitivity and specificity than any other prognostic melanoma test.

Back to Our Portfolio

Believe in Ideas. Start your investment journey today.

View our Funds